Inmunoglobulina g intravenosa experiencia terapéutica en pacientes con necrolisis epidérmica tóxica y/o síndrome de Stevens Jonhson en Bogotá, Colombia

El síndrome de Stevens–Johnson (SSJ) y la necrólisis epidérmica tóxica (NET) son reacciones medicamentosas graves que forman parte de un mismo espectro de enfermedad. Ambas entidades se deben a la apoptosis masiva de queratinocitos. El objetivo del estudio fue describir los desenlaces clínicos con e...

Full description

Autores:
Ibagón Pardo, Viviana del Pilar
Ordóñez Rubiano, María Fernanda
Tipo de recurso:
Fecha de publicación:
2019
Institución:
Universidad Militar Nueva Granada
Repositorio:
Repositorio UMNG
Idioma:
spa
OAI Identifier:
oai:repository.unimilitar.edu.co:10654/34911
Acceso en línea:
http://hdl.handle.net/10654/34911
Palabra clave:
NECROLISIS EPIDERMICA TOXICA
INMUNOGLOBULINA G INTRAVENOSA
SINDROME DE STEVENS JOHNSON
Toxic epidermal necrolysis
Intravenous immunoglobulin
Stevens Johnson sindrome.
Management
Treatment
DERMATOLOGIA
NECROSIS
MANIFESTACIONES CUTANEAS DE ENFERMEDADES GENERALES
Necrólisis epidérmica tóxica
Inmunoglobulina G intravenosa
Síndrome de Stevens Johnson
Manejo
Tratamiento
Rights
License
Derechos Reservados - Universidad Militar Nueva Granada, 2020
id UNIMILTAR2_54cd6e106b76060198e6d84d85f28035
oai_identifier_str oai:repository.unimilitar.edu.co:10654/34911
network_acronym_str UNIMILTAR2
network_name_str Repositorio UMNG
repository_id_str
dc.title.spa.fl_str_mv Inmunoglobulina g intravenosa experiencia terapéutica en pacientes con necrolisis epidérmica tóxica y/o síndrome de Stevens Jonhson en Bogotá, Colombia
dc.title.translated.spa.fl_str_mv Intravenous g immunoglobulin therapeutic experience in patients with toxic epidermal necrolisis and Stevens-Johnson syndrome in Bogotá Colombia
title Inmunoglobulina g intravenosa experiencia terapéutica en pacientes con necrolisis epidérmica tóxica y/o síndrome de Stevens Jonhson en Bogotá, Colombia
spellingShingle Inmunoglobulina g intravenosa experiencia terapéutica en pacientes con necrolisis epidérmica tóxica y/o síndrome de Stevens Jonhson en Bogotá, Colombia
NECROLISIS EPIDERMICA TOXICA
INMUNOGLOBULINA G INTRAVENOSA
SINDROME DE STEVENS JOHNSON
Toxic epidermal necrolysis
Intravenous immunoglobulin
Stevens Johnson sindrome.
Management
Treatment
DERMATOLOGIA
NECROSIS
MANIFESTACIONES CUTANEAS DE ENFERMEDADES GENERALES
Necrólisis epidérmica tóxica
Inmunoglobulina G intravenosa
Síndrome de Stevens Johnson
Manejo
Tratamiento
title_short Inmunoglobulina g intravenosa experiencia terapéutica en pacientes con necrolisis epidérmica tóxica y/o síndrome de Stevens Jonhson en Bogotá, Colombia
title_full Inmunoglobulina g intravenosa experiencia terapéutica en pacientes con necrolisis epidérmica tóxica y/o síndrome de Stevens Jonhson en Bogotá, Colombia
title_fullStr Inmunoglobulina g intravenosa experiencia terapéutica en pacientes con necrolisis epidérmica tóxica y/o síndrome de Stevens Jonhson en Bogotá, Colombia
title_full_unstemmed Inmunoglobulina g intravenosa experiencia terapéutica en pacientes con necrolisis epidérmica tóxica y/o síndrome de Stevens Jonhson en Bogotá, Colombia
title_sort Inmunoglobulina g intravenosa experiencia terapéutica en pacientes con necrolisis epidérmica tóxica y/o síndrome de Stevens Jonhson en Bogotá, Colombia
dc.creator.fl_str_mv Ibagón Pardo, Viviana del Pilar
Ordóñez Rubiano, María Fernanda
dc.contributor.advisor.spa.fl_str_mv Amador Patarroyo, Julio Roberto
dc.contributor.author.spa.fl_str_mv Ibagón Pardo, Viviana del Pilar
Ordóñez Rubiano, María Fernanda
dc.contributor.other.spa.fl_str_mv Amador Patarroyo, Julio Roberto
Cortés Correa, Carolina
dc.contributor.corporatename.spa.fl_str_mv Hospital Militar Central Bogotá, Colombia
Hospital Universitario de la Samaritana Bogotá, Colombia
Clínica el Country Bogotá, Colombia
dc.subject.lemb.spa.fl_str_mv NECROLISIS EPIDERMICA TOXICA
INMUNOGLOBULINA G INTRAVENOSA
SINDROME DE STEVENS JOHNSON
topic NECROLISIS EPIDERMICA TOXICA
INMUNOGLOBULINA G INTRAVENOSA
SINDROME DE STEVENS JOHNSON
Toxic epidermal necrolysis
Intravenous immunoglobulin
Stevens Johnson sindrome.
Management
Treatment
DERMATOLOGIA
NECROSIS
MANIFESTACIONES CUTANEAS DE ENFERMEDADES GENERALES
Necrólisis epidérmica tóxica
Inmunoglobulina G intravenosa
Síndrome de Stevens Johnson
Manejo
Tratamiento
dc.subject.keywords.spa.fl_str_mv Toxic epidermal necrolysis
Intravenous immunoglobulin
Stevens Johnson sindrome.
Management
Treatment
dc.subject.decs.none.fl_str_mv DERMATOLOGIA
NECROSIS
MANIFESTACIONES CUTANEAS DE ENFERMEDADES GENERALES
dc.subject.proposal.spa.fl_str_mv Necrólisis epidérmica tóxica
Inmunoglobulina G intravenosa
Síndrome de Stevens Johnson
Manejo
Tratamiento
description El síndrome de Stevens–Johnson (SSJ) y la necrólisis epidérmica tóxica (NET) son reacciones medicamentosas graves que forman parte de un mismo espectro de enfermedad. Ambas entidades se deben a la apoptosis masiva de queratinocitos. El objetivo del estudio fue describir los desenlaces clínicos con el tratamiento de inmunoglobulina G humana intravenosa (IgG-IV) en los pacientes diagnosticados con SSJ y/o NET tratados en 3 instituciones de Bogotá.
publishDate 2019
dc.date.issued.none.fl_str_mv 2019-11-06
dc.date.accessioned.none.fl_str_mv 2020-02-25T18:06:21Z
dc.date.available.none.fl_str_mv 2020-02-25T18:06:21Z
dc.type.spa.fl_str_mv info:eu-repo/semantics/bachelorThesis
dc.type.coar.fl_str_mv http://purl.org/coar/resource_type/c_7a1f
dc.type.local.spa.fl_str_mv Trabajo de grado
dc.type.dcmi-type-vocabulary.spa.fl_str_mv Text
dc.identifier.uri.none.fl_str_mv http://hdl.handle.net/10654/34911
url http://hdl.handle.net/10654/34911
dc.language.iso.spa.fl_str_mv spa
spa
language spa
dc.relation.references.spa.fl_str_mv 1. Gupta LK, Martin AM, Agarwal N, D'Souza P, Das S, Kumar R, et al. Guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis: An Indian perspective. Indian J Dermatol Venereol Leprol. 2016;82(6):603-25.
2. Barron SJ, Del Vecchio MT, Aronoff SC. Intravenous immunoglobulin in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis: a meta-analysis with meta-regression of observational studies. Int J Dermatol. 2015;54(1):108-15.
3. Griffiths Ce, Barker JMDe, Bleiker Te, Chalmers Re, Creamer De, Rook ATod. Rook's Textbook of dermatology. Ninth edition. ed.
4. Tan SK, Tay YK. Profile and pattern of Stevens-Johnson syndrome and toxic epidermal necrolysis in a general hospital in Singapore: treatment outcomes. Acta Derm Venereol. 2012;92(1):62-6.
5. Comparin C, Hans Filho G, Takita LC, Costa Nde C, Nascimento RA, Nanni Lde O. Treatment of toxic epidermal necrolysis with intravenous immunoglobulin: a series of three cases. An Bras Dermatol. 2012;87(3):477-81.
6. Creamer D, Walsh SA, Dziewulski P, Exton LS, Lee HY, Dart JK, et al. U.K. guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults 2016. Br J Dermatol. 2016;174(6):1194-227.
7. Miliszewski MA, Kirchhof MG, Sikora S, Papp A, Dutz JP. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: An Analysis of Triggers and Implications for Improving Prevention. Am J Med. 2016;129(11):1221-5.
8. Lalosevic J, Nikolic M, Gajic-Veljic M, Skiljevic D, Medenica L. Stevens-Johnson syndrome and toxic epidermal necrolysis: a 20-year single-center experience. Int J Dermatol. 2015;54(8):978-84.
9. Zajicek R, Pintar D, Broz L, Suca H, Konigova R. Toxic epidermal necrolysis and Stevens-Johnson syndrome at the Prague Burn Centre 1998-2008. J Eur Acad Dermatol Venereol. 2012;26(5):639-43.
10. Zhang AJ, Nygaard RM, Endorf FW, Hylwa SA. Stevens-Johnson syndrome and toxic epidermal necrolysis: retrospective review of 10-year experience. Int J Dermatol. 2019;58(9):1069-77.
11. Firoz BF, Henning JS, Zarzabal LA, Pollock BH. Toxic epidermal necrolysis: five years of treatment experience from a burn unit. J Am Acad Dermatol. 2012;67(4):630-5.
12. McCullough M, Burg M, Lin E, Peng D, Garner W. Steven Johnson Syndrome and Toxic Epidermal Necrolysis in a burn unit: A 15-year experience. Burns. 2017;43(1):200-5.
13. Dodiuk-Gad RP, Chung WH, Valeyrie-Allanore L, Shear NH. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: An Update. Am J Clin Dermatol. 2015;16(6):475-93.
14. Tran AK, Sidhu S. Stevens Johnson syndrome and toxic epidermal necrolysis - an Australian analysis of treatment outcomes and mortality. J Dermatolog Treat. 2019;30(7):718-23.
15. Yamane Y, Matsukura S, Watanabe Y, Yamaguchi Y, Nakamura K, Kambara T, et al. Retrospective analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis in 87 Japanese patients--Treatment and outcome. Allergol Int. 2016;65(1):74-81.
16. Bequignon E, Duong TA, Sbidian E, Valeyrie-Allanore L, Ingen-Housz-Oro S, Chatelin V, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: ear, nose, and throat description at acute stage and after remission. JAMA Dermatol. 2015;151(3):302-7.
17. Stella M, Clemente A, Bollero D, Risso D, Dalmasso P. Toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS): experience with high-dose intravenous immunoglobulins and topical conservative approach. A retrospective analysis. Burns. 2007;33(4):452-9.
18. Martinez-Cabriales SA, Gomez-Flores M, Ocampo-Candiani J. [News in severe clinical adverse drug reactions: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN)]. Gac Med Mex. 2015;151(6):777-87.
19. Roujeau JC, Bastuji-Garin S. Systematic review of treatments for Stevens-Johnson syndrome and toxic epidermal necrolysis using the SCORTEN score as a tool for evaluating mortality. Ther Adv Drug Saf. 2011;2(3):87-94.
20. Micheletti RG, Chiesa-Fuxench Z, Noe MH, Stephen S, Aleshin M, Agarwal A, et al. Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: A Multicenter Retrospective Study of 377 Adult Patients from the United States. J Invest Dermatol. 2018;138(11):2315-21.
21. Chen J, Wang B, Zeng Y, Xu H. High-dose intravenous immunoglobulins in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis in Chinese patients: a retrospective study of 82 cases. Eur J Dermatol. 2010;20(6):743-7.
22. Yang Y, Xu J, Li F, Zhu X. Combination therapy of intravenous immunoglobulin and corticosteroid in the treatment of toxic epidermal necrolysis and Stevens-Johnson syndrome: a retrospective comparative study in China. Int J Dermatol. 2009;48(10):1122-8.
23. Viard I, Wehrli P, Bullani R, Schneider P, Holler N, Salomon D, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science. 1998;282(5388):490-3.
24. Prins C, Kerdel FA, Padilla RS, Hunziker T, Chimenti S, Viard I, et al. Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases. Arch Dermatol. 2003;139(1):26-32.
25. Huang YC, Li YC, Chen TJ. The efficacy of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis: a systematic review and meta-analysis. Br J Dermatol. 2012;167(2):424-32.
26. Campione E, Marulli GC, Carrozzo AM, Chimenti MS, Costanzo A, Bianchi L. High-dose intravenous immunoglobulin for severe drug reactions: efficacy in toxic epidermal necrolysis. Acta Derm Venereol. 2003;83(6):430-2.
27. Trent JT, Kirsner RS, Romanelli P, Kerdel FA. Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN: The University of Miami Experience. Arch Dermatol. 2003;139(1):39-43.
28. Enk AH, Hadaschik EN, Eming R, Fierlbeck G, French LE, Girolomoni G, et al. European Guidelines (S1) on the use of high-dose intravenous immunoglobulin in dermatology. J Eur Acad Dermatol Venereol. 2016;30(10):1657-69.
29. Yeung CK, Lam LK, Chan HH. The timing of intravenous immunoglobulin therapy in Stevens-Johnson syndrome and toxic epidermal necrolysis. Clin Exp Dermatol. 30. England2005. p. 600-2.
30. Esquivel A, Horcasitas R, Peralta M, Vázquez A. Guía de Práctica Clínica Diagnóstico y Tratamiento del Síndrome de Stevens Johnson/Necrólisis Epidérmica Tóxica. México: Secretaria de Salud 2011.
31. Olmos É, Ortiz J. Reacciones severas medicamentosas: síndrome de stevens johnson/necrólisis toxicoepidérmica. In: Correa Serna L, editor. Guías para manejo de urgencias: tomo II Ministerio de la Protección Social. Bogotá: Imprenta Nacional de Colombia; 2009. p. 436-9.
32. David Andrés A, Paola Andrea L, Juana Gabriela L, Luis Hernando M. Síndrome de Stevens-Johnson y necrólisis epidérmica tóxica en el Hospital Universitario del Valle “Evaristo García” durante un periodo de 9 años. Revista de la Asociación Colombiana de Dermatología y Cirugía Dermatológica. 2013;21(3).
dc.rights.spa.fl_str_mv Derechos Reservados - Universidad Militar Nueva Granada, 2020
dc.rights.coar.fl_str_mv http://purl.org/coar/access_right/c_abf2
dc.rights.uri.spa.fl_str_mv https://creativecommons.org/licenses/by-nc-nd/2.5/co/
dc.rights.creativecommons.spa.fl_str_mv Atribución-NoComercial-SinDerivadas
rights_invalid_str_mv Derechos Reservados - Universidad Militar Nueva Granada, 2020
https://creativecommons.org/licenses/by-nc-nd/2.5/co/
Atribución-NoComercial-SinDerivadas
http://purl.org/coar/access_right/c_abf2
dc.format.spa.fl_str_mv pdf
dc.format.mimetype.spa.fl_str_mv application/pdf
dc.coverage.spatial.spa.fl_str_mv Medicina
dc.publisher.spa.fl_str_mv Universidad Militar Nueva Granada
dc.publisher.department.spa.fl_str_mv Facultad de Medicina
dc.publisher.program.spa.fl_str_mv Dermatología
dc.publisher.faculty.spa.fl_str_mv Medicina y Ciencias de la Salud - Dermatología
institution Universidad Militar Nueva Granada
bitstream.url.fl_str_mv http://repository.unimilitar.edu.co/bitstream/10654/34911/1/IbagonPardoVivianadelPilar2019.pdf
http://repository.unimilitar.edu.co/bitstream/10654/34911/2/license.txt
http://repository.unimilitar.edu.co/bitstream/10654/34911/3/IbagonPardoVivianadelPilar2019.pdf.jpg
bitstream.checksum.fl_str_mv 9e6774fd40a7a4fdbdf08cbff12c648b
a609d7e369577f685ce98c66b903b91b
aa1c7c2e77d3b0761f52a2cee3d434cc
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
repository.name.fl_str_mv Repositorio Institucional UMNG
repository.mail.fl_str_mv bibliodigital@unimilitar.edu.co
_version_ 1814090659676553216
spelling Amador Patarroyo, Julio RobertoIbagón Pardo, Viviana del PilarOrdóñez Rubiano, María FernandaEspecialista en DermatologíaAmador Patarroyo, Julio RobertoCortés Correa, CarolinaHospital Militar Central Bogotá, ColombiaHospital Universitario de la Samaritana Bogotá, ColombiaClínica el Country Bogotá, ColombiaMedicina2020-02-25T18:06:21Z2020-02-25T18:06:21Z2019-11-06http://hdl.handle.net/10654/34911El síndrome de Stevens–Johnson (SSJ) y la necrólisis epidérmica tóxica (NET) son reacciones medicamentosas graves que forman parte de un mismo espectro de enfermedad. Ambas entidades se deben a la apoptosis masiva de queratinocitos. El objetivo del estudio fue describir los desenlaces clínicos con el tratamiento de inmunoglobulina G humana intravenosa (IgG-IV) en los pacientes diagnosticados con SSJ y/o NET tratados en 3 instituciones de Bogotá.ÍNDICE DE CONTENIDO • RESUMEN ESTRUCTURADO--------------------------------------------- 4 • IDENTIFICACIÓN Y FORMULACIÓN DEL PROBLEMA--------------9 • OBJETIVOS E HIPÓTESIS------------------------------------------------- 11 • METODOLOGÍA------------------------------------------------------------ 12 • PLAN DE ANÁLISIS-------------------------------------------------------- 20 • ASPECTOS ÉTICOS--------------------------------------------------------- 21 • RESULTADOS--------------------------------------------------------------- 22 • DISCUSIÓN------------------------------------------------------------------ 29 • CONCLUSIONES------------------------------------------------------------ 32 • REFERENCIAS BIBLIOGRÁFICAS-----------------------------------------33 • ANEXOS-----------------------------------------------------------------------36Stevens-Johnson syndrome (SJS) and toxic epidermal necrólisis (TEN) are life-threatening drug reactions considered to be part of a single spectrum disease. Both entities are due to massive keratinocyte apoptosis. The aim of this study was to describe the clinical outcomes with the treatment of intravenous human G immunoglobulin (IVIg) in patients diagnosed with SJS/TEN treated in 3 institutions in Bogotá.Especializaciónpdfapplication/pdfspaspaUniversidad Militar Nueva GranadaFacultad de MedicinaDermatologíaMedicina y Ciencias de la Salud - DermatologíaDerechos Reservados - Universidad Militar Nueva Granada, 2020https://creativecommons.org/licenses/by-nc-nd/2.5/co/Atribución-NoComercial-SinDerivadashttp://purl.org/coar/access_right/c_abf2Inmunoglobulina g intravenosa experiencia terapéutica en pacientes con necrolisis epidérmica tóxica y/o síndrome de Stevens Jonhson en Bogotá, ColombiaIntravenous g immunoglobulin therapeutic experience in patients with toxic epidermal necrolisis and Stevens-Johnson syndrome in Bogotá Colombiainfo:eu-repo/semantics/bachelorThesisTrabajo de gradoTexthttp://purl.org/coar/resource_type/c_7a1fNECROLISIS EPIDERMICA TOXICAINMUNOGLOBULINA G INTRAVENOSASINDROME DE STEVENS JOHNSONToxic epidermal necrolysisIntravenous immunoglobulinStevens Johnson sindrome.ManagementTreatmentDERMATOLOGIANECROSISMANIFESTACIONES CUTANEAS DE ENFERMEDADES GENERALESNecrólisis epidérmica tóxicaInmunoglobulina G intravenosaSíndrome de Stevens JohnsonManejoTratamiento1. Gupta LK, Martin AM, Agarwal N, D'Souza P, Das S, Kumar R, et al. Guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis: An Indian perspective. Indian J Dermatol Venereol Leprol. 2016;82(6):603-25.2. Barron SJ, Del Vecchio MT, Aronoff SC. Intravenous immunoglobulin in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis: a meta-analysis with meta-regression of observational studies. Int J Dermatol. 2015;54(1):108-15.3. Griffiths Ce, Barker JMDe, Bleiker Te, Chalmers Re, Creamer De, Rook ATod. Rook's Textbook of dermatology. Ninth edition. ed.4. Tan SK, Tay YK. Profile and pattern of Stevens-Johnson syndrome and toxic epidermal necrolysis in a general hospital in Singapore: treatment outcomes. Acta Derm Venereol. 2012;92(1):62-6.5. Comparin C, Hans Filho G, Takita LC, Costa Nde C, Nascimento RA, Nanni Lde O. Treatment of toxic epidermal necrolysis with intravenous immunoglobulin: a series of three cases. An Bras Dermatol. 2012;87(3):477-81.6. Creamer D, Walsh SA, Dziewulski P, Exton LS, Lee HY, Dart JK, et al. U.K. guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults 2016. Br J Dermatol. 2016;174(6):1194-227.7. Miliszewski MA, Kirchhof MG, Sikora S, Papp A, Dutz JP. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: An Analysis of Triggers and Implications for Improving Prevention. Am J Med. 2016;129(11):1221-5.8. Lalosevic J, Nikolic M, Gajic-Veljic M, Skiljevic D, Medenica L. Stevens-Johnson syndrome and toxic epidermal necrolysis: a 20-year single-center experience. Int J Dermatol. 2015;54(8):978-84.9. Zajicek R, Pintar D, Broz L, Suca H, Konigova R. Toxic epidermal necrolysis and Stevens-Johnson syndrome at the Prague Burn Centre 1998-2008. J Eur Acad Dermatol Venereol. 2012;26(5):639-43.10. Zhang AJ, Nygaard RM, Endorf FW, Hylwa SA. Stevens-Johnson syndrome and toxic epidermal necrolysis: retrospective review of 10-year experience. Int J Dermatol. 2019;58(9):1069-77.11. Firoz BF, Henning JS, Zarzabal LA, Pollock BH. Toxic epidermal necrolysis: five years of treatment experience from a burn unit. J Am Acad Dermatol. 2012;67(4):630-5.12. McCullough M, Burg M, Lin E, Peng D, Garner W. Steven Johnson Syndrome and Toxic Epidermal Necrolysis in a burn unit: A 15-year experience. Burns. 2017;43(1):200-5.13. Dodiuk-Gad RP, Chung WH, Valeyrie-Allanore L, Shear NH. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: An Update. Am J Clin Dermatol. 2015;16(6):475-93.14. Tran AK, Sidhu S. Stevens Johnson syndrome and toxic epidermal necrolysis - an Australian analysis of treatment outcomes and mortality. J Dermatolog Treat. 2019;30(7):718-23.15. Yamane Y, Matsukura S, Watanabe Y, Yamaguchi Y, Nakamura K, Kambara T, et al. Retrospective analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis in 87 Japanese patients--Treatment and outcome. Allergol Int. 2016;65(1):74-81.16. Bequignon E, Duong TA, Sbidian E, Valeyrie-Allanore L, Ingen-Housz-Oro S, Chatelin V, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: ear, nose, and throat description at acute stage and after remission. JAMA Dermatol. 2015;151(3):302-7.17. Stella M, Clemente A, Bollero D, Risso D, Dalmasso P. Toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS): experience with high-dose intravenous immunoglobulins and topical conservative approach. A retrospective analysis. Burns. 2007;33(4):452-9.18. Martinez-Cabriales SA, Gomez-Flores M, Ocampo-Candiani J. [News in severe clinical adverse drug reactions: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN)]. Gac Med Mex. 2015;151(6):777-87.19. Roujeau JC, Bastuji-Garin S. Systematic review of treatments for Stevens-Johnson syndrome and toxic epidermal necrolysis using the SCORTEN score as a tool for evaluating mortality. Ther Adv Drug Saf. 2011;2(3):87-94.20. Micheletti RG, Chiesa-Fuxench Z, Noe MH, Stephen S, Aleshin M, Agarwal A, et al. Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: A Multicenter Retrospective Study of 377 Adult Patients from the United States. J Invest Dermatol. 2018;138(11):2315-21.21. Chen J, Wang B, Zeng Y, Xu H. High-dose intravenous immunoglobulins in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis in Chinese patients: a retrospective study of 82 cases. Eur J Dermatol. 2010;20(6):743-7.22. Yang Y, Xu J, Li F, Zhu X. Combination therapy of intravenous immunoglobulin and corticosteroid in the treatment of toxic epidermal necrolysis and Stevens-Johnson syndrome: a retrospective comparative study in China. Int J Dermatol. 2009;48(10):1122-8.23. Viard I, Wehrli P, Bullani R, Schneider P, Holler N, Salomon D, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science. 1998;282(5388):490-3.24. Prins C, Kerdel FA, Padilla RS, Hunziker T, Chimenti S, Viard I, et al. Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases. Arch Dermatol. 2003;139(1):26-32.25. Huang YC, Li YC, Chen TJ. The efficacy of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis: a systematic review and meta-analysis. Br J Dermatol. 2012;167(2):424-32.26. Campione E, Marulli GC, Carrozzo AM, Chimenti MS, Costanzo A, Bianchi L. High-dose intravenous immunoglobulin for severe drug reactions: efficacy in toxic epidermal necrolysis. Acta Derm Venereol. 2003;83(6):430-2.27. Trent JT, Kirsner RS, Romanelli P, Kerdel FA. Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN: The University of Miami Experience. Arch Dermatol. 2003;139(1):39-43.28. Enk AH, Hadaschik EN, Eming R, Fierlbeck G, French LE, Girolomoni G, et al. European Guidelines (S1) on the use of high-dose intravenous immunoglobulin in dermatology. J Eur Acad Dermatol Venereol. 2016;30(10):1657-69.29. Yeung CK, Lam LK, Chan HH. The timing of intravenous immunoglobulin therapy in Stevens-Johnson syndrome and toxic epidermal necrolysis. Clin Exp Dermatol. 30. England2005. p. 600-2.30. Esquivel A, Horcasitas R, Peralta M, Vázquez A. Guía de Práctica Clínica Diagnóstico y Tratamiento del Síndrome de Stevens Johnson/Necrólisis Epidérmica Tóxica. México: Secretaria de Salud 2011.31. Olmos É, Ortiz J. Reacciones severas medicamentosas: síndrome de stevens johnson/necrólisis toxicoepidérmica. In: Correa Serna L, editor. Guías para manejo de urgencias: tomo II Ministerio de la Protección Social. Bogotá: Imprenta Nacional de Colombia; 2009. p. 436-9.32. David Andrés A, Paola Andrea L, Juana Gabriela L, Luis Hernando M. Síndrome de Stevens-Johnson y necrólisis epidérmica tóxica en el Hospital Universitario del Valle “Evaristo García” durante un periodo de 9 años. Revista de la Asociación Colombiana de Dermatología y Cirugía Dermatológica. 2013;21(3).ORIGINALIbagonPardoVivianadelPilar2019.pdfIbagonPardoVivianadelPilar2019.pdfapplication/pdf1247640http://repository.unimilitar.edu.co/bitstream/10654/34911/1/IbagonPardoVivianadelPilar2019.pdf9e6774fd40a7a4fdbdf08cbff12c648bMD51LICENSElicense.txtlicense.txttext/plain; charset=utf-83420http://repository.unimilitar.edu.co/bitstream/10654/34911/2/license.txta609d7e369577f685ce98c66b903b91bMD52THUMBNAILIbagonPardoVivianadelPilar2019.pdf.jpgIbagonPardoVivianadelPilar2019.pdf.jpgIM Thumbnailimage/jpeg6967http://repository.unimilitar.edu.co/bitstream/10654/34911/3/IbagonPardoVivianadelPilar2019.pdf.jpgaa1c7c2e77d3b0761f52a2cee3d434ccMD5310654/34911oai:repository.unimilitar.edu.co:10654/349112020-09-03 01:03:53.36Repositorio Institucional UMNGbibliodigital@unimilitar.edu.coRWwgYXV0b3IgZGUgbGEgb2JyYSAodGVzaXMsIG1vbm9ncmFmw61hLCB0cmFiYWpvIGRlIGdyYWRvIG8gY3VhbHF1aWVyIG90cm8gZG9jdW1lbnRvCmNvbiBjYXLDoWN0ZXIgYWNhZMOpbWljbyksIGFjdHVhbmRvIGVuIG5vbWJyZSBwcm9waW8sIGhhY2UgZW50cmVnYSBkZWwgZWplbXBsYXIgcmVzcGVjdGl2bwp5IGRlIHN1cyBhbmV4b3MgZW4gZm9ybWF0byBkaWdpdGFsIG8gZWxlY3Ryw7NuaWNvLgoKRUwgRVNUVURJQU5URSAtIEFVVE9SLCBtYW5pZmllc3RhIHF1ZSBsYSBvYnJhIG9iamV0byBkZSBsYSBwcmVzZW50ZSBhdXRvcml6YWNpw7NuCmVzIG9yaWdpbmFsIHkgbGEgcmVhbGl6w7Mgc2luIHZpb2xhciBvIHVzdXJwYXIgZGVyZWNob3MgZGUgYXV0b3IgZGUgdGVyY2Vyb3MsIHBvcgpsbyB0YW50bywgbGEgb2JyYSBlcyBkZSBleGNsdXNpdmEgYXV0b3LDrWEgeSB0aWVuZSBsYSB0aXR1bGFyaWRhZCBzb2JyZSBsYSBtaXNtYS4KCkVuIGNhc28gZGUgcHJlc2VudGFyc2UgY3VhbHF1aWVyIHJlY2xhbWFjacOzbiBvIGFjY2nDs24gcG9yIHBhcnRlIGRlIHVuIHRlcmNlcm8gZW4KY3VhbnRvIGEgbG9zIGRlcmVjaG9zIGRlIGF1dG9yIHNvYnJlIGxhIG9icmEgZW4gY3Vlc3Rpw7NuLCBFTCBFU1RVRElBTlRFIC0gQVVUT1IsCmFzdW1pcsOhIHRvZGEgbGEgcmVzcG9uc2FiaWxpZGFkLCB5IHNhbGRyw6EgZW4gZGVmZW5zYSBkZSBsb3MgZGVyZWNob3MgYXF1w60gYXV0b3JpemFkb3M7CnBhcmEgdG9kb3MgbG9zIGVmZWN0b3MgbGEgdW5pdmVyc2lkYWQgYWN0w7phIGNvbW8gdW4gdGVyY2VybyBkZSBidWVuYSBmZS4KCkFkZW3DoXMsICJMQSBVTklWRVJTSURBRCBNSUxJVEFSIE5VRVZBIEdSQU5BREEgY29tbyBpbnN0aXR1Y2nDs24gcXVlIGFsbWFjZW5hLCB5CnJlY29sZWN0YSBkYXRvcyBwZXJzb25hbGVzLCBhdGVuZGllbmRvIGxvIHByZWNlcHR1YWRvIGVuIGxhIGxleSAxNTgxIGRlIDIwMTIgeSBlbApEZWNyZXRvIDEzNzcgZGUgMjAxMywgcXVlIGRlc2Fycm9sbGFuIGVsIHByaW5jaXBpbyBjb25zdGl0dWNpb25hbCBxdWUgdGllbmVuIHRvZGFzCmxhcyBwZXJzb25hcyBhIGNvbm9jZXIsIGFjdHVhbGl6YXIgeSByZWN0aWZpY2FyIHRvZG8gdGlwbyBkZSBpbmZvcm1hY2nDs24gcmVjb2dpZGEKbywgcXVlIGhheWEgc2lkbyBvYmpldG8gZGUgdHJhdGFtaWVudG8gZGUgZGF0b3MgcGVyc29uYWxlcyBlbiBiYW5jb3MgbyBiYXNlcyBkZQpkYXRvcyB5IGVuIGdlbmVyYWwgZW4gYXJjaGl2b3MgZGUgZW50aWRhZGVzIHDDumJsaWNhcyBvIHByaXZhZGFzLCByZXF1aWVyZSBvYnRlbmVyCnN1IGF1dG9yaXphY2nDs24sIHBhcmEgcXVlLCBkZSBtYW5lcmEgbGlicmUsIHByZXZpYSwgZXhwcmVzYSwgdm9sdW50YXJpYSwgeQpkZWJpZGFtZW50ZSBpbmZvcm1hZGEsIHBlcm1pdGEgYSB0b2RhcyBudWVzdHJhcyBkZXBlbmRlbmNpYXMgYWNhZMOpbWljYXMgeQphZG1pbmlzdHJhdGl2YXMsIHJlY29sZWN0YXIsIHJlY2F1ZGFyLCBhbG1hY2VuYXIsIHVzYXIsIGNpcmN1bGFyLCBzdXByaW1pciwgcHJvY2VzYXIsCmNvbXBpbGFyLCBpbnRlcmNhbWJpYXIsIGRhciB0cmF0YW1pZW50bywgYWN0dWFsaXphciB5IGRpc3BvbmVyIGRlIGxvcyBkYXRvcyBxdWUKaGFuIHNpZG8gc3VtaW5pc3RyYWRvcyB5IHF1ZSBzZSBoYW4gaW5jb3Jwb3JhZG8gZW4gbnVlc3RyYXMgYmFzZXMgbyBiYW5jb3MgZGUKZGF0b3MsIG8gZW4gcmVwb3NpdG9yaW9zIGVsZWN0csOzbmljb3MgZGUgdG9kbyB0aXBvIGNvbiBxdWUgY3VlbnRhIGxhIFVuaXZlcnNpZGFkLgoKRXN0YSBpbmZvcm1hY2nDs24gZXMgeSBzZXLDoSB1dGlsaXphZGEgZW4gZWwgZGVzYXJyb2xsbyBkZSBsYXMgZnVuY2lvbmVzIHByb3BpYXMgZGUKbGEgVW5pdmVyc2lkYWQgZW4gc3UgY29uZGljacOzbiBkZSBpbnN0aXR1Y2nDs24gZGUgZWR1Y2FjacOzbiBzdXBlcmlvciwgZGUgZm9ybWEKZGlyZWN0YSBvIGEgdHJhdsOpcyBkZSB0ZXJjZXJvcyIuCgpTaSBzdSBkb2N1bWVudG8gZXMgZGUgYWNjZXNvIHJlc3RyaW5naWRvICwgc3UgdHJhYmFqbyBzZSBkZXBvc2l0YXLDoSBlbiBlbApSZXBvc2l0b3JpbyBVTU5HIMO6bmljYW1lbnRlIGNvbiBwcm9ww7NzaXRvcyBkZSBwcmVzZXJ2YWNpw7NuIGRvY3VtZW50YWwgeSBtZW1vcmlhCmluc3RpdHVjaW9uYWwsIGVudGVuZGllbmRvIHF1ZSwgc2Vyw6EgY29uc3VsdGFkbyBkZSBmb3JtYSBjb250cm9sYWRhIHNvbGFtZW50ZSBwb3IKbGEgY29tdW5pZGFkIE5lb2dyYW5hZGluYS4KClNpIHN1IGRvY3VtZW50byBlcyBkZSBhY2Nlc28gYWJpZXJ0bywgcGFyYSBwZXJtaXRpciBhbCBSZXBvc2l0b3JpbyBVTU5HIHJlcHJvZHVjaXIsCnRyYWR1Y2lyIHkgZGlzdHJpYnVpciBzdSBlbnbDrW8gYSB0cmF2w6lzIGRlbCBtdW5kbywgbmVjZXNpdGFtb3Mgc3UgY29uZm9ybWlkYWQgZW4KbG9zIHNpZ3VpZW50ZXMgdMOpcm1pbm9zOgoKWSBhdXRvcml6YSBhIGxhIFVOSVZFUlNJREFEIE1JTElUQVIgTlVFVkEgR1JBTkFEQSwgcGFyYSBxdWUgZW4gbG9zIHTDqXJtaW5vcwplc3RhYmxlY2lkb3MgZW46CgpMZXkgMjMgZGUgMTk4Mi0gTGV5IDQ0IGRlIDE5OTMgLUxleSAxOTE1IGRlIDIwMTggLSBEZWNpc2nDs24gQW5kaW5hIDM1MSBkZSAxOTkzLQpEZWNyZXRvIDQ2MCBkZSAxOTk1IHkgZGVtw6FzIG5vcm1hcyBnZW5lcmFsZXMgc29icmUgbGEgbWF0ZXJpYSwgdXRpbGljZSB5IHVzZSBwb3IKY3VhbHF1aWVyIG1lZGlvIGNvbm9jaWRvIG8gcG9yIGNvbm9jZXIsIGxvcyBkZXJlY2hvcyBwYXRyaW1vbmlhbGVzIGRlIHJlcHJvZHVjY2nDs24sCmNvbXVuaWNhY2nDs24gcMO6YmxpY2EsIHRyYW5zZm9ybWFjacOzbiB5IGRpc3RyaWJ1Y2nDs24gZGUgbGEgb2JyYSBvYmpldG8gZGVsIHByZXNlbnRlCmRvY3VtZW50by4KCkxhIHByZXNlbnRlIGF1dG9yaXphY2nDs24gc2UgaGFjZSBleHRlbnNpdmEgbm8gc8OzbG8gYSBsYXMgZmFjdWx0YWRlcyB5IGRlcmVjaG9zIGRlCnVzbyBzb2JyZSBsYSBvYnJhIGVuIGZvcm1hdG8gbyBzb3BvcnRlIG1hdGVyaWFsLCBzaW5vIHRhbWJpw6luIHBhcmEgZm9ybWF0byB2aXJ0dWFsLAplbGVjdHLDs25pY28sIGRpZ2l0YWwsIHkgY3V5byB1c28gc2UgZGUgZW4gcmVkLCBpbnRlcm5ldCwgZXh0cmFuZXQsIGludHJhbmV0LCBldGMuLAp5IGVuIGdlbmVyYWwgZW4gY3VhbHF1aWVyIGZvcm1hdG8gY29ub2NpZG8gbyBwb3IgY29ub2Nlci4KClNpIHRpZW5lIGFsZ3VuYSBkdWRhIHNvYnJlIGxvcyBUw6lybWlub3MgeSBjb25kaWNpb25lcywgcG9yIGZhdm9yLCBjb250YWN0ZSBjb24gZWwKYWRtaW5pc3RyYWRvciBkZWwgc2lzdGVtYSBiaWJsaW9kaWdpdGFsQHVuaW1pbGl0YXIuZWR1LmNvCgpBY2VwdGUgVMOpcm1pbm9zIHkgY29uZGljaW9uZXMgc2VsZWNjaW9uYW5kbyAiQWNlcHRvIiB5IHB1bHNhbmRvICJDb21wbGV0YXIgZW52w61vIi4K

Publicaciones similares